Teleflex
Market Cap
US$16.0b
Last Updated
2020/02/28 00:36 UTC
Data Sources
Company Financials +
Executive Summary
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Solid track record with mediocre balance sheet.
Similar Companies
Share Price & News
How has Teleflex's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TFX has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-9.0%
TFX
-9.3%
US Medical Equipment
-10.6%
US Market
1 Year Return
14.5%
TFX
6.2%
US Medical Equipment
5.2%
US Market
Return vs Industry: TFX exceeded the US Medical Equipment industry which returned 10.7% over the past year.
Return vs Market: TFX exceeded the US Market which returned 10.2% over the past year.
Shareholder returns
| TFX | Industry | Market | |
|---|---|---|---|
| 7 Day | -9.0% | -9.3% | -10.6% |
| 30 Day | -11.1% | -9.4% | -8.5% |
| 90 Day | -4.6% | -5.0% | -4.6% |
| 1 Year | 14.9%14.5% | 7.1%6.2% | 7.4%5.2% |
| 3 Year | 76.1%73.5% | 60.4%55.9% | 31.7%23.2% |
| 5 Year | 189.0%179.4% | 95.6%74.9% | 56.4%39.3% |
Price Volatility Vs. Market
How volatile is Teleflex's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
Teleflex Incorporated Just Released Its Yearly Results And Analysts Are Updating Their Estimates1 week ago | Simply Wall St
Is Teleflex (NYSE:TFX) A Risky Investment?3 weeks ago | Simply Wall St
Investors Who Bought Teleflex (NYSE:TFX) Shares Five Years Ago Are Now Up 244%Valuation
Is Teleflex undervalued compared to its fair value and its price relative to the market?
3.1%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: TFX ($345.3) is trading below our estimate of fair value ($347.63)
Significantly Below Fair Value: TFX is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: TFX is good value based on its PE Ratio (34.5x) compared to the Medical Equipment industry average (45.3x).
PE vs Market: TFX is poor value based on its PE Ratio (34.5x) compared to the US market (17.1x).
Price to Earnings Growth Ratio
PEG Ratio: TFX is poor value based on its PEG Ratio (2.8x)
Price to Book Ratio
PB vs Industry: TFX is overvalued based on its PB Ratio (5.4x) compared to the US Medical Equipment industry average (3.9x).
Next Steps
Future Growth
How is Teleflex forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?
12.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TFX's forecast earnings growth (12.5% per year) is above the savings rate (1.7%).
Earnings vs Market: TFX's earnings (12.5% per year) are forecast to grow slower than the US market (13.2% per year).
High Growth Earnings: TFX's earnings are forecast to grow, but not significantly.
Revenue vs Market: TFX's revenue (6.5% per year) is forecast to grow slower than the US market (7.6% per year).
High Growth Revenue: TFX's revenue (6.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TFX's Return on Equity is forecast to be low in 3 years time (19.1%).
Next Steps
Past Performance
How has Teleflex performed over the past 5 years?
7.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TFX has high quality earnings.
Growing Profit Margin: TFX's current net profit margins (17.8%) are higher than last year (8%).
Past Earnings Growth Analysis
Earnings Trend: TFX's earnings have grown by 7.3% per year over the past 5 years.
Accelerating Growth: TFX's earnings growth over the past year (135.2%) exceeds its 5-year average (7.3% per year).
Earnings vs Industry: TFX earnings growth over the past year (135.2%) exceeded the Medical Equipment industry 1.4%.
Return on Equity
High ROE: TFX's Return on Equity (15.5%) is considered low.
Next Steps
Financial Health
How is Teleflex's financial position?
Financial Position Analysis
Short Term Liabilities: TFX's short term assets ($1.3B) exceed its short term liabilities ($563.1M).
Long Term Liabilities: TFX's short term assets ($1.3B) do not cover its long term liabilities ($2.8B).
Debt to Equity History and Analysis
Debt Level: TFX's debt to equity ratio (64.1%) is considered high.
Reducing Debt: TFX's debt to equity ratio has increased from 55.9% to 64.1% over the past 5 years.
Debt Coverage: TFX's debt is well covered by operating cash flow (23%).
Interest Coverage: TFX's interest payments on its debt are well covered by EBIT (6.3x coverage).
Balance Sheet
Inventory Level: TFX has a low level of unsold assets or inventory.
Debt Coverage by Assets: TFX's debt is not covered by short term assets (assets are 0.7x debt).
Next Steps
Dividend
What is Teleflex's current dividend yield, its reliability and sustainability?
0.40%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: TFX's dividend (0.39%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.53%).
High Dividend: TFX's dividend (0.39%) is low compared to the top 25% of dividend payers in the US market (3.96%).
Stability and Growth of Payments
Stable Dividend: TFX is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: TFX is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: TFX is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TFX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.6yrs
Average management tenure
CEO
Liam Kelly (52yo)
2.1yrs
Tenure
US$6,108,486
Compensation
Mr. Liam J. Kelly has been Chief Executive Officer at Teleflex Incorporated since January 01, 2018 and has been its Director since May 4, 2018. He serves as Director of Colfax Corporation since January 1, ...
CEO Compensation Analysis
Compensation vs Market: Liam's total compensation ($USD6.11M) is below average for companies of similar size in the US market ($USD10.78M).
Compensation vs Earnings: Liam's compensation has increased by more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.1yrs | US$6.11m | 0.020% $3.2m | |
| Executive VP & CFO | 7.9yrs | US$2.89m | 0.010% $1.7m | |
| Corporate VP | 6yrs | US$1.45m | 0.025% $4.1m | |
| Corporate VP of Global Human Resources & Employee Communications | 6.8yrs | US$1.13m | 0.011% $1.7m | |
| VP & Chief Accounting Officer | 2.8yrs | no data | 0.0029% $467.5k | |
| VP & Chief Information Officer | 7.3yrs | no data | no data | |
| Treasurer & VP of Investor Relations | 0yrs | no data | no data | |
| Chief Compliance Officer & VP | 0yrs | no data | no data | |
| Vice President of Global Corporate Development | 6.6yrs | no data | no data | |
| President & GM of Interventional Urology | 0yrs | no data | no data |
6.6yrs
Average Tenure
52yo
Average Age
Experienced Management: TFX's management team is seasoned and experienced (6.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.1yrs | US$6.11m | 0.020% $3.2m | |
| Lead Director | 0yrs | US$278.45k | 0.022% $3.5m | |
| Independent Director | 1.1yrs | no data | 0.0027% $432.3k | |
| Independent Director | 3.4yrs | US$239.40k | 0.0046% $742.8k | |
| Independent Director | 2.8yrs | US$239.40k | 0.0043% $685.2k | |
| Chairman of the Board | 9.1yrs | US$318.31k | 0.10% $16.5m | |
| Independent Director | 10.8yrs | US$259.40k | 0.0047% $749.2k | |
| Independent Director | 2.1yrs | US$372.08k | 0.0032% $518.7k | |
| Independent Director | 11.8yrs | US$236.40k | 0.019% $3.0m | |
| Independent Director | 4.8yrs | US$246.06k | 0.0044% $707.6k |
3.4yrs
Average Tenure
64yo
Average Age
Experienced Board: TFX's board of directors are considered experienced (3.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Teleflex Incorporated's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Teleflex Incorporated
- Ticker: TFX
- Exchange: NYSE
- Founded: 1943
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$16.009b
- Shares outstanding: 46.36m
- Website: https://www.teleflex.com
Number of Employees
Location
- Teleflex Incorporated
- 550 East Swedesford Road
- Suite 400
- Wayne
- Pennsylvania
- 19087
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TFX | NYSE (New York Stock Exchange) | Yes | Common Shares | US | USD | Jan 1968 |
| TBH | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Jan 1968 |
| T1FX34 | BOVESPA (Bolsa de Valores de Sao Paulo) | BDR EACH 10 REPR 1 COM | BR | BRL | Jan 2020 |
Biography
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease. The company also provides interventional access products that are used in dialysis, oncology, and critical care therapies; and cardiac care products, such as diagnostic and intra-aortic balloon catheters, and capital equipment. In addition, it offers anesthesia products, such as pain management products for use in surgical and obstetric procedures; airway management products and related devices for use in pre-hospital emergency and hospital settings; and other pre-hospital emergency products. Further, the company offers surgical products, including Weck Ligation Systems, Weck EFx Fascial Closure Systems, Percutaneous Surgical Systems, Weck Vista bladeless access ports, Deknatel sutures, and Pilling and Kmedic surgical instruments; products for use in acute care settings for diagnostic and therapeutic procedures, and in general and specialty surgical applications; and single-use respiratory, urology, and interventional urology products. Additionally, it provides devices and instruments for other medical device manufacturers, such as custom-engineered extrusions, diagnostic and interventional catheters, balloon sheath/dilator sets and kits, sutures, performance fibers, and bioresorbable resins and fibers. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was founded in 1943 and is headquartered in Wayne, Pennsylvania.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/28 00:36 |
| End of Day Share Price | 2020/02/27 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.